CN109928964B - 一种阿西替尼中间体的合成方法 - Google Patents
一种阿西替尼中间体的合成方法 Download PDFInfo
- Publication number
- CN109928964B CN109928964B CN201711364991.1A CN201711364991A CN109928964B CN 109928964 B CN109928964 B CN 109928964B CN 201711364991 A CN201711364991 A CN 201711364991A CN 109928964 B CN109928964 B CN 109928964B
- Authority
- CN
- China
- Prior art keywords
- compound
- solution
- temperature
- reaction
- dichloromethane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 title claims abstract description 13
- 229960003005 axitinib Drugs 0.000 title claims abstract description 11
- 238000010189 synthetic method Methods 0.000 title claims abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 51
- 238000006243 chemical reaction Methods 0.000 claims description 25
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 24
- 239000007864 aqueous solution Substances 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 16
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 14
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 12
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000011259 mixed solution Substances 0.000 claims description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 claims description 8
- 235000010288 sodium nitrite Nutrition 0.000 claims description 8
- ORZRMRUXSPNQQL-UHFFFAOYSA-N 6-nitro-1h-indazole Chemical compound [O-][N+](=O)C1=CC=C2C=NNC2=C1 ORZRMRUXSPNQQL-UHFFFAOYSA-N 0.000 claims description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 6
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 claims description 6
- 235000019270 ammonium chloride Nutrition 0.000 claims description 6
- 239000011630 iodine Substances 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 5
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 5
- AKICECWDRFGXGN-UHFFFAOYSA-N pyridine triphenylphosphane Chemical compound C1=CC=NC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 AKICECWDRFGXGN-UHFFFAOYSA-N 0.000 claims description 5
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 3
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 238000003756 stirring Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000001816 cooling Methods 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 238000000967 suction filtration Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 238000004537 pulping Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000006192 iodination reaction Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229940005319 inlyta Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- -1 small molecule tyrosine kinase inhibitor Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711364991.1A CN109928964B (zh) | 2017-12-18 | 2017-12-18 | 一种阿西替尼中间体的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711364991.1A CN109928964B (zh) | 2017-12-18 | 2017-12-18 | 一种阿西替尼中间体的合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109928964A CN109928964A (zh) | 2019-06-25 |
CN109928964B true CN109928964B (zh) | 2022-04-15 |
Family
ID=66982505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711364991.1A Active CN109928964B (zh) | 2017-12-18 | 2017-12-18 | 一种阿西替尼中间体的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109928964B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009036066A1 (en) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
CN103387565A (zh) * | 2013-07-29 | 2013-11-13 | 苏州明锐医药科技有限公司 | 阿西替尼的制备方法 |
CN103570696A (zh) * | 2013-11-06 | 2014-02-12 | 湖南欧亚生物有限公司 | 一种阿西替尼中间体的制备方法以及在制备阿西替尼中的应用 |
CN103826618A (zh) * | 2011-09-30 | 2014-05-28 | 辉瑞大药厂 | N-甲基-2-[3-((e)-2-吡啶-2-基-乙烯基)-1h-吲唑-6-基硫烷基]苯甲酰胺的药物组合物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9580406B2 (en) * | 2015-04-28 | 2017-02-28 | Signa S.A. De C.V. | Processes for the preparation of axitinib |
-
2017
- 2017-12-18 CN CN201711364991.1A patent/CN109928964B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009036066A1 (en) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
CN103826618A (zh) * | 2011-09-30 | 2014-05-28 | 辉瑞大药厂 | N-甲基-2-[3-((e)-2-吡啶-2-基-乙烯基)-1h-吲唑-6-基硫烷基]苯甲酰胺的药物组合物 |
CN103387565A (zh) * | 2013-07-29 | 2013-11-13 | 苏州明锐医药科技有限公司 | 阿西替尼的制备方法 |
CN103570696A (zh) * | 2013-11-06 | 2014-02-12 | 湖南欧亚生物有限公司 | 一种阿西替尼中间体的制备方法以及在制备阿西替尼中的应用 |
Non-Patent Citations (3)
Title |
---|
Synthesis, antitumor evaluation, and molecular docking studies of indole–indazolyl hydrazide–hydrazone derivatives;Sreenivasulu, R et al.;《Monatshefte Fur Chemie》;20160421;第148卷(第2期);第305-314页 * |
阿西替尼的合成;郝桂运等;《中国药物化学杂志》;20140831;第24卷(第4期);第298-302页 * |
阿西替尼的合成工艺研究;徐辰等;《沈阳药科大学学报》;20140930;第31卷(第9期);第677-680页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109928964A (zh) | 2019-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104497014A (zh) | 一种手性氟喹诺酮C-3稠杂环α,β-不饱和酮衍生物及其制备方法和应用 | |
CN106243031B (zh) | 一种阿帕替尼的制备方法 | |
CN102391287B (zh) | 左旋氟喹诺酮c3双唑甲硫醚、制备方法及其应用 | |
CN109867734A (zh) | 一类咖啡酸修饰的环糊精衍生物及其制备方法 | |
CN108290867A (zh) | 一种制备酪氨酸激酶抑制剂及其衍生物的方法 | |
CN102190628B (zh) | 一种5-氟-6-乙基-4-羟基嘧啶中间体及伏立康唑的制备方法 | |
CN109776419A (zh) | 含有吡唑啉基团的硫鎓盐及其制备方法和应用 | |
CN104592252B (zh) | 一种噁嗪并喹啉酮c-3均三唑硫醚酮缩氨基硫脲衍生物及其制备方法和应用 | |
EP3956321A1 (en) | Process for preparing axitinib, process for purifying the intermediate 2-((3-iodo-1h-indazol-6-yl)thio)-n-methylbenzamide, process for purifying axitinib via the axitinib hcl salt, solid form of the axitinib hcl salt | |
CN109928964B (zh) | 一种阿西替尼中间体的合成方法 | |
CN102443011B (zh) | 左旋氟喹诺酮c3双唑甲硫醚季铵盐、制备方法及其应用 | |
TWI699362B (zh) | 光學活性異唑啉化合物之製備方法 | |
CN105330560A (zh) | 一种恩杂鲁胺中间体的制备方法 | |
CN103588765B (zh) | 阿齐沙坦酯或其盐的合成方法及其中间体和中间体的合成方法 | |
CN104892602A (zh) | 一种1,2,4-三唑[4,3-a]吡啶环的腙衍生物及其制备与应用 | |
WO2015110654A1 (en) | Process of production of 2,3,6-trimethylphenol | |
CN113072481B (zh) | 一种吲哚并环丁烷骨架类化合物、合成方法及应用 | |
CN114213424A (zh) | 一种呋喃[3,2-b]并吡啶衍生物的合成方法 | |
CN104530088A (zh) | 2-氨基-6,7-二氢-5H-噻唑并[5,4-b]吡啶-4-羧酸叔丁酯及其衍生物,以及它们的合成方法 | |
CN104557768A (zh) | 一种苯并噻唑衍生物的合成方法 | |
CN101885708B (zh) | 5-多氟烷基取代的2-氨基噻唑类化合物、合成方法及其应用 | |
CN109705027A (zh) | 1,2-二(吡啶基)-3,4-二(4-吡啶乙烯基-3-氟苯)环丁烷及其制备方法 | |
CN105130973A (zh) | 5-吡啶基-2-氨基-苯并[d]噁唑衍生物及其制备方法和用途 | |
CN103980208A (zh) | 厄洛替尼及其衍生物的制备方法 | |
CN111377858A (zh) | 一种米力农的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Synthesis Method of Acetinib Intermediate Effective date of registration: 20230711 Granted publication date: 20220415 Pledgee: Agricultural Bank of China Limited Nanjing Qixia Branch Pledgor: SKYRUN PHARMA Co.,Ltd. Registration number: Y2023980048064 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231107 Granted publication date: 20220415 Pledgee: Agricultural Bank of China Limited Nanjing Qixia Branch Pledgor: SKYRUN PHARMA Co.,Ltd. Registration number: Y2023980048064 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |